Amicogen Inc (092040) Fair Value & Analysis
Healthcare · KR · Market cap 82.4B KRW
Fair value as of: Aug 13, 2026
From 3 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from 146.52 KRW to 137.82 KRW (−5.9%) since Jul 20, 2026. Share price −12.1% over the past month.
Below-average quality, and screening another 86% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (157.19 KRW). The favourable scenario is already priced in.
- Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 970.00 KRW – 20,964 KRW · fair‑value band 125.23 KRW – 157.19 KRW · the 1,000 KRW price screens above the 137.82 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Amicogen Inc (092040) currently trades at 1,000 KRW, while our model-based Fair Value estimate is 137.82 KRW, implying the stock looks roughly 86.2% overvalued today. The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Amicogen Inc generated revenue of 43.4B KRW at a net margin of -10.5%. Revenue grew 13.5% year over year. It earns a return on equity of -4.0%. Net debt stands at 86.8B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 125.23 KRW (bear case) to 157.19 KRW (bull case); at 1,000 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 77% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -86%, 092040 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (899.32 KRW) versus Dividend Discount (130.03 KRW). Highest evidence: Gordon GGM (70).
Notify me when 092040 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food.
Full company description
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company offers oral incurable and rare disease treatments, as well as manufactures and sells of pharmaceutical raw materials, animal drugs, human drugs, etc. The company was incorporated in 2000 and is headquartered in Jinju-Si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Amicogen Inc reported revenue of 42.0B KRW in FY2025 versus 125B KRW in FY2021, a compound −23.9%/yr. Reported net income was −30.0B KRW in FY2025.
092040 screens 86% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 633 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Amicogen Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Amicogen Inc (092040) overvalued or undervalued?
What is the fair value of 092040?
What is the quality score of 092040?
What is the revenue of Amicogen Inc (092040)?
What is the net profit margin of 092040?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Amicogen Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.